Home / Publication / Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data

論文

Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data

Author(s): Takahisa Kawamura, Hidefumi Kasai, Valentina Fermanelli, Toshiaki Takahashi, Yukinori Sakata, Toshiyuki Matsuoka, Mika Ishii, Yusuke Tanigawara

Year: 2018年6月22日

How Model-informed drug development rescue projects from a risky situation

事例紹介

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

論文

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

ウェビナー

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

ウェビナー

Powered by Translations.com GlobalLink Web Software

Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data

Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data

How Model-informed drug development rescue projects from a risky situation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data

How Model-informed drug development rescue projects from a risky situation​

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation